Stock Market & Financial Investment News

News Breaks April 2, 2012 05:35 EDT NVS Novartis QVA149 Phase III COPD studies meet primary endpoints The first three Novartis QVA149 Phase III studies in the treatment of chronic obstructive pulmonary disease, or COPD, all met their primary endpoints. The SHINE, BRIGHT and ENLIGHTEN studies, which are key components of the IGNITE program, demonstrate the potential of QVA149 in the treatment of COPD. "Meeting the primary endpoints in the IGNITE Phase III clinical trial program signals significant progress in establishing the potential of QVA149, which is expected to be the third innovative medicine in our strong COPD portfolio," said Tim Wright, Head of Development, Novartis Pharmaceuticals. News For NVS From The Last 14 Days Check below for free stories on NVS the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 21, 2013 07:44 EDT NVS Sachs Associates to host a forum Subscribe for More Information 07:24 EDT NVS Global Health Care to host a conference Subscribe for More Information May 20, 2013 07:29 EDT NVS Deutsche Bank to host a conference dbAccess Asia Conference 2013 is being held in Singapore on May 20-22. May 17, 2013 16:20 EDT NVS Novartis drug Afinitor extended time without disease progression in women Subscribe for More Information May 16, 2013 08:11 EDT NVS Novartis says no intention of pursuing Actavis, Bloomberg reports Subscribe for More Information May 15, 2013 19:37 EDT NVS Novartis weighing Actavis bid, WSJ reports Subscribe for More Information 18:17 EDT NVS Novartis weighs possible bid for Actavis, DJ reports Subscribe for More Information May 10, 2013 05:42 EDT NVS Novartis drug Ilaris approved by FDA Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.